This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Fatty Acid Oxidation Disorders / MCAD Deficiency지방산대사장애

Contents and key points
ItemDetails
A. Classification codesICD-10: E71.3 (Disorders of fatty-acid metabolism) | Special Copayment Reduction: V117 (ultra-rare disease, copayment exempt)
B. SynonymsFatty acid oxidation disorders (FAO disorders), medium-chain acyl-CoA dehydrogenase deficiency (MCAD deficiency, MCADD), short-chain acyl-CoA dehydrogenase deficiency (SCAD deficiency), mitochondrial fatty acid beta-oxidation defects, ACADM deficiency
C. Adult onsetLikelihood of first onset in adulthood is not low — there are cases diagnosed at the first metabolic crisis in adulthood (hypoglycemia or rhabdomyolysis after fasting, surgery or infection) in carriers of mild variants or patients born before the era of newborn screening. In particular, in MCADD, hypoglycemic crises can occur in adults under metabolic stress, so diagnosis in adulthood is possible.
1. HistoryGregersen describes FAO disorders in 1973 → MCAD deficiency enzyme identified in 1982 → c.985A>G founder variant discovered in 1990 → MS/MS newborn screening introduced in the 1990s → worldwide expansion of screening in the 2000s.
2. CausesDeficiency of mitochondrial fatty acid beta-oxidation enzymes (MCAD, SCAD, etc.). MCADD is caused by ACADM gene (1p31) variants. Energy deficiency during fasting, accumulation of toxic acylcarnitines.
3. GeneticsAutosomal recessive. ACADM gene 1p31. The Northern European founder variant c.985A>G (p.Lys329Glu) in 80–90% of European patients. Various rare variants in Asians.
4. General epidemiologyMCADD 1:10,000–15,000 births in Northern Europe. Rarer in Asia. MCADD is the most common of all FAO disorders (about 50%).
5. PathophysiologyMCAD deficiency → impaired oxidation of medium-chain acyl-CoA → inability to produce ketones during fasting → hypoketotic hypoglycemia. Accumulation of C8, C6, C10 acylcarnitines. Energy deficiency of the liver, heart and brain.
6. SymptomsFasting-induced hypoglycemia in infancy, hypotonia, lethargy, vomiting, seizures, decreased consciousness. Sudden death possible at the first episode. Adults: rhabdomyolysis, hypoglycemia.
7. SignsHypoketotic hypoglycemia, hepatomegaly, hyperammonemia, elevated AST/ALT. Elevated plasma octanoylcarnitine (C8) is the key screening marker.
8. ScreeningNewborn MS/MS - analysis of C8, C6, C10 and the C8/C10 ratio on dried blood spots (DBS). The main marker of MCADD is marked elevation of C8.
9. DiagnosisPlasma acylcarnitine analysis + urine organic acid analysis + ACADM gene analysis. Enzyme activity measurement. Preservation of acute-phase specimens is important.
10. TreatmentAvoid fasting (regular feeding), intravenous glucose in the acute phase, carry an emergency plan card. Ketogenic diet contraindicated. Selective carnitine supplementation. Metabolic consultation before surgery.
11. PrognosisNormal development possible with early management after newborn screening. Mortality at the first episode before screening about 20–25%. Regular feeding and adherence to emergency guidelines determine prognosis.
12. PreventionNewborn MS/MS screening, genetic counseling, emergency education for parents, metabolic consultation before surgery and anesthesia, carrying an emergency protocol card.
13. ReferencesGrosse SD et al. Genet Med. 2006 (PMID 16980815) … and 9 other papers

1. History

Clinical recognition of fatty acid oxidation disorders (FAO disorders) began in the early 1970s. In 1973, Gregersen and colleagues in Denmark first systematically described a group of metabolic diseases caused by enzyme deficiencies of the fatty acid beta-oxidation pathway and proposed that fasting-triggered hypoglycemia and ketone deficiency are the main clinical features. In 1976, as DiMauro and DiMauro reported muscle carnitine palmitoyltransferase (CPT) deficiency, the clinical spectrum of FAO disorders began to expand.

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (MCADD) was first characterized at the enzyme level in 1982 through independent publications by Kolvraa and colleagues and Gregersen and colleagues. The MCAD enzyme is a FAD-dependent enzyme that processes medium-chain fatty acids with 6–12 carbons in the mitochondrial beta-oxidation pathway, and its deficiency was shown to be a major cause of hypoketotic hypoglycemia and acute encephalopathy. In 1985 the ACADM gene was cloned, and in 1990 Tanaka and colleagues reported the landmark finding that a single founder variant (c.985A>G, p.Lys329Glu) is found in about 90% of MCADD patients of European descent, laying the foundation for molecular diagnosis.

The revolutionary turning point in the diagnosis of FAO disorders was the development of newborn screening technology using tandem mass spectrometry (MS/MS) in the early 1990s. When Millington and colleagues (1990) developed a method for analyzing acylcarnitine profiles from dried blood spots (DBS), it became possible to screen for various FAO disorders, including MCADD, with a single test. In the United States, MS/MS-based expanded newborn screening expanded nationwide from the early 2000s, and in Korea, acylcarnitine analysis was introduced after 2005 as part of the newborn metabolic disease screening program. Before the introduction of newborn screening, about 20–25% of MCADD patients died or suffered permanent neurological damage at the first episode, but after screening this proportion decreased dramatically. Today, MCADD is cited as a representative success story of newborn screening programs. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency was first reported in 1984, but controversy over its clinical significance continues, and long-chain FAO disorders (VLCAD, LCHAD, CPT1/2 deficiency) are each covered in detail in separate files.


2. Causes

Fatty acid oxidation disorders (FAO disorders) are a group of inherited metabolic diseases caused by deficiencies of various enzymes or transport proteins involved in the mitochondrial fatty acid beta-oxidation pathway. Fatty acid oxidation is the key pathway of energy supply in situations in which glucose is depleted, such as fasting, strenuous exercise, fever, surgery and stress, and when this process is blocked, hypoglycemia, ketone deficiency and accumulation of toxic metabolites occur.

MCAD deficiency (MCADD), the most common FAO disorder, results from reduced or absent mitochondrial medium-chain acyl-CoA dehydrogenase (MCAD) activity due to pathogenic variants of the ACADM gene (short arm of chromosome 1, 1p31). MCAD is a FAD-dependent enzyme that catalyzes the dehydrogenation of acyl-CoA compounds with 6–12 carbons (medium chain) and is responsible for the first step of the mitochondrial beta-oxidation spiral. A single founder variant c.985A>G (p.Lys329Glu) is found in about 80–90% of patients of Northern European descent. This variant causes protein misfolding and increased degradation of the enzyme protein, so that MCAD activity is almost lost.

SCAD deficiency results from deficiency of short-chain acyl-CoA dehydrogenase due to ACADS gene (12q24.31) variants and is characterized by increased excretion of butyrylcarnitine (C4) and ethylmalonic acid. Many patients with SCAD deficiency are clinically asymptomatic or have mild symptoms, so there is controversy over its pathogenic significance. The common pathophysiology of FAO disorders is the suppression of ketone body synthesis as production of acetyl-CoA from fatty acids becomes impossible. In the fasting state, after glycogen depletion, the ketone bodies (beta-hydroxybutyrate, acetoacetate) that should be produced by activated fatty acid beta-oxidation cannot be synthesized, resulting in hypoketotic hypoglycemia. In addition, partially oxidized toxic acylcarnitines accumulate, causing cellular dysfunction, arrhythmias, hepatotoxicity and so on.


3. Genetics

All FAO disorders follow an autosomal recessive mode of inheritance. ACADM, the causative gene of MCADD, is located on the short arm of chromosome 1 (1p31.1), is about 44 kb long and consists of 12 exons. The encoded MCAD precursor protein (421 amino acids) forms a homotetrameric structure after cleavage of the mitochondrial targeting sequence and functions in the mitochondrial matrix. The founder variant c.985A>G (p.Lys329Glu) in patients of Northern European descent is located in exon 11 and substitutes glutamic acid for lysine at position 329, causing protein misfolding and impaired tetramer assembly. The carrier frequency of this variant in Europe is about 1:40–1:100, and patients homozygous for c.985A>G account for about 70–80% of all MCADD.

In MCADD patients of Asian descent (including Korea), the c.985A>G variant is very rare, and various rare or private variants are found. The molecular genetic profile of Korean MCADD patients has not yet been sufficiently characterized, but data are accumulating with the spread of NGS-based diagnosis. In ACADS (12q24.31), the causative gene of SCADD, the c.511C>T (p.Arg171Trp) and c.625G>A (p.Gly209Ser) variants are frequently reported, and their clinical significance when present alone or in a compound heterozygous state with pathogenic variants is controversial. Genetic testing is performed with NGS-based metabolic disease panels, WES or WGS and is used as standard in the confirmation process after a positive newborn screen. In the case of compound heterozygous variants, parental testing is needed to confirm phase, and for rare variants functional study data are limited, so caution is needed in interpretation.


4. General epidemiology

MCADD is the most common form of all FAO disorders, with an incidence of about 1 in 10,000–15,000 births in populations of Northern European descent. In some Northern European countries (UK, Germany, Denmark), a higher frequency of 1 in 8,000–10,000 births is reported. Because the carrier frequency of the c.985A>G founder variant is particularly high in Northern European populations, since the introduction of MS/MS newborn screening MCADD has been one of the diseases with the highest detection rates among screened conditions. In Asian populations, the incidence is lower than in Northern Europe, with reports of about 1 in 50,000 births in newborn screening data from Taiwan and about 1 in 40,000–90,000 in Japan.

There are insufficient data on the exact incidence in Korea, but diagnosed cases are gradually increasing since the expansion of newborn screening. Adding up the incidence of all FAO disorders gives an estimate of about 1 in 5,000–10,000 births. FAO disorders sometimes show particular ethnic predilections. CPT1A deficiency shows a very high frequency (1:50–1:100 births) in Alaska Native and Canadian Inuit populations, and LCHAD deficiency is relatively often reported in Northern Europe (especially Finland). In data from the era before newborn screening, MCADD phenotypic penetrance was high, and most patients developed metabolic crises when exposed to environmental triggers (fasting, infection). In patient cohorts diagnosed after screening, the proportion of asymptomatic or mild phenotypes tends to be higher. It occurs with equal frequency in females and males, and the age of onset is mainly from a few months of life to within 2 years, but first symptoms can also appear in adults.


5. Pathophysiology

Mitochondrial fatty acid beta-oxidation is a repeated enzymatic reaction that sequentially cleaves long-chain, medium-chain and short-chain fatty acids in two-carbon units (acetyl-CoA). Each cycle consists of the acyl-CoA dehydrogenase reaction, the enoyl-CoA hydratase reaction, the 3-hydroxyacyl-CoA dehydrogenase reaction and the 3-ketoacyl-CoA thiolase reaction. Of these, MCAD is responsible for the first dehydrogenation step of medium-chain (C6–C12) acyl-CoA.

The core pathophysiology of MCAD deficiency arises from the blockade of medium-chain fatty acid oxidation during fasting or hypercatabolic states. Normally, after glycogen depletion, fatty acid beta-oxidation is activated and ketone bodies (beta-hydroxybutyrate, acetoacetate) are produced from acetyl-CoA, supplying the main energy source for the brain, heart and muscles. In MCAD deficiency, medium-chain fatty acids cannot be converted to acetyl-CoA, so ketone body production is severely limited, and hypoketotic hypoglycemia appears, in which the brain cannot use ketone bodies as an alternative energy source even when hypoglycemia occurs. This is the direct cause of acute encephalopathy due to brain energy deficiency (decreased consciousness, seizures, coma).

When medium-chain acyl-CoAs (octanoyl-CoA, hexanoyl-CoA, decanoyl-CoA, etc.) are not degraded and accumulate, they are converted by carnitine acyltransferases to the corresponding acylcarnitines (C8, C6, C10 acylcarnitines) and released into the blood. Elevated plasma C8 (octanoylcarnitine) is the diagnostic marker of MCADD. High concentrations of medium-chain acylcarnitines and medium-chain fatty acids disrupt cell membrane integrity, inhibit the mitochondrial electron transport chain, and cause hepatocyte dysfunction and myocardial electrophysiological abnormalities (arrhythmias). In the liver, fat deposition, glycogen depletion, elevated transaminases and hyperammonemia may appear. SCAD deficiency is characterized by accumulation of butyrylcarnitine (C4) and ethylmalonic acid due to blockade of short-chain acyl-CoA (butyryl-CoA, C4) oxidation. The main triggers are fever and increased metabolic rate due to infection, poor feeding due to vomiting, and preoperative fasting.


6. Symptoms

The clinical symptoms of FAO disorders, including MCADD, typically appear in the form of acute metabolic crises triggered by factors such as fasting, infection, surgery and fever. Because patients may appear clinically completely normal in symptom-free intervals, it is important to suspect FAO disorders promptly in acute episodes.

Acute metabolic crises in infancy and early childhood typically begin at 2–24 months of age with poor feeding and vomiting after viral gastroenteritis or upper respiratory infection. Beginning with lethargy and hypotonia, they progress within hours to decreased consciousness, seizures and coma. Hepatomegaly is often present. When blood glucose is measured, hypoglycemia (usually below 50 mg/dL) is confirmed, characteristically with almost no or very low ketones. Without treatment, acute brain injury or death can result, and presentation as sudden death at the first episode has also been reported. For this reason, in the past some MCADD deaths may have been misclassified as sudden infant death syndrome (SIDS) of unknown cause.

Patients diagnosed through newborn screening can remain symptom-free when appropriately managed. Some patients may have exercise intolerance, chronic fatigue, recurrent vomiting or loss of appetite. Presentation in adults includes cases in which symptoms first appear as a hypoglycemic crisis or rhabdomyolysis after prolonged fasting, excessive exercise, pregnancy, alcohol intake or fever. First presentation in adults has also been reported as sudden death or liver failure, so FAO disorders should be included in the differential diagnosis in adult patients as well.


7. Signs

The most characteristic laboratory finding of an acute metabolic crisis is hypoketotic hypoglycemia. A pattern of blood glucose below 50 mg/dL with markedly low or negative blood and urine ketones is a diagnostic clue. Plasma acylcarnitine analysis confirms marked elevation of octanoylcarnitine (C8), accompanied by elevation of hexanoylcarnitine (C6) and decanoylcarnitine (C10) and an increased C8/C10 ratio. Urine organic acids show abnormal organic acids such as suberylglycine, 5-hydroxyhexanoic acid and octanoylglycine. Findings of liver dysfunction, such as elevated aminotransferases (AST, ALT), hyperammonemia and PT prolongation, may accompany these. Reduced free carnitine and an increased acylcarnitine ratio appear.

On physical examination, hypotonia, decreased consciousness, hepatomegaly and jaundice may be observed in the acute phase. Cardiomyopathy and myocarditis are particularly prominent in long-chain FAO disorders, but cardiac arrhythmias can also occur in the acute phase of severe MCADD. With rhabdomyolysis, extreme CK elevation and myoglobinuria are observed. With acute encephalopathy, brain MRI may show abnormal signals in the basal ganglia and white matter and cerebral edema. Liver ultrasound sometimes shows fatty liver and increased hepatic echogenicity. In patients diagnosed through newborn screening, only the biochemical abnormality of elevated plasma C8 may be found at routine checkups, without a metabolic crisis.


8. Screening

The standard for newborn screening for FAO disorders, including MCADD, is acylcarnitine profile analysis of dried blood spots (DBS) using tandem mass spectrometry (MS/MS). DBS collected 24–72 hours after birth (usually after 48 hours) are analyzed by flow injection analysis with derivatization or by non-derivatized methods. The main screening markers of MCADD are as follows.

When the initial screen is positive, confirmatory tests include repeat plasma acylcarnitine analysis, urine organic acid analysis and ACADM gene testing. Because acylcarnitines may normalize on the second screening test in some patients (wash-out effect), referral to a specialized metabolic disease center is recommended after a first positive result regardless of the second test result. In Korea, MS/MS-based acylcarnitine analysis is included in the newborn screening program, so newborns suspected of FAO disorders, including MCADD, are referred early to specialized metabolic disease centers.


9. Diagnosis

MCADD is confirmed through stepwise testing after a positive newborn screen or in a situation of clinical suspicion. Both biochemical and molecular genetic confirmation are needed. On plasma acylcarnitine analysis, elevated C8 (octanoylcarnitine) is the key finding. It is particularly prominent in acute-phase blood specimens, and because levels may fall or normalize in the interval phase, acute-phase specimens or specimens after sufficient fasting are advantageous for diagnosis.

Urine organic acid analysis (GC-MS) confirms the presence of organic acids specific to MCAD deficiency, such as suberylglycine, octanoylglycine and 5-hydroxyhexanoic acid. Levels may be lower in the interval phase. ACADM gene analysis identifies pathogenic variants by Sanger sequencing or NGS-based panels. Confirmation of c.985A>G homozygosity is sufficient for confirmation. Enzyme activity measurement is diagnostic when MCAD enzyme activity in cultured skin fibroblasts or lymphocytes is below 10% of normal controls, but now that gene analysis is standardized it is used as an adjunct. When a hypoketotic hypoglycemia pattern is identified in an infant with unexplained decreased consciousness, seizures or hypoglycemia, specimens for plasma acylcarnitine and urine organic acid analysis are immediately obtained and stored frozen, and a metabolic disease specialist is consulted while intravenous glucose is given.


10. Treatment

Treatment of MCADD centers on preventive management, with avoidance of fasting at its core, and on glucose supplementation during acute metabolic crises. Currently there is no enzyme replacement therapy or gene therapy that fundamentally treats MCADD, and appropriate lifestyle management and education are the core of treatment. In infants, regular feeding is maintained to limit fasting time. Newborn to 3 months: maximum fasting 4 hours. 3–12 months: maximum 8 hours. 1–7 years: maximum 10–12 hours. 7 years and older and adults: maintained at a maximum of 12 hours.

As an emergency protocol, the patient's caregivers always carry an emergency guideline card. When visiting the emergency department, this card is presented so that 10% glucose infusion (intravenous at 8–10 mg/kg/min) can be started immediately. In hypercatabolic states such as infection, fever and preoperative fasting, fasting is kept much shorter than the standard fasting time, and when oral intake is not possible, the patient immediately visits a medical institution to start intravenous glucose supplementation. For surgery, the anesthesia department is notified of the MCADD diagnosis in advance, and shortened preoperative fasting and maintenance of intraoperative glucose infusion are planned. As for diet, a ketogenic diet (high-fat, low-carbohydrate diet) is absolutely contraindicated, and large intakes of foods rich in medium-chain fatty acids (coconut oil, etc.) are also avoided. When plasma free carnitine is markedly low, L-carnitine can be supplemented selectively, but evidence for the benefit of routine administration is unclear.


11. Prognosis

The prognosis of MCADD depends decisively on the timing of diagnosis and the level of subsequent management. In patients diagnosed early through newborn screening who adhere to fasting avoidance and the emergency protocol, normal or near-normal neurological development and life expectancy are possible. Long-term follow-up of screen-detected MCADD patients in large cohort studies in the UK and Europe reported that neurocognitive development, academic achievement and quality of life were at levels similar to the general population.

In the era before newborn screening, mortality at the first episode reached about 20–25%, and many survivors had neurological sequelae (intellectual disability, epilepsy, motor disorders). Even after diagnosis, acute metabolic crises can cause brain injury, cardiac arrhythmias and liver failure, so continued adherence to preventive management is key. Prompt emergency treatment during hypercatabolic episodes is decisive in preventing acute complications. In patients diagnosed in adulthood, neurological damage that has already occurred may be irreversible, but further metabolic crises can be prevented through management after diagnosis. In the long term, complications are detected early and managed through periodic plasma acylcarnitine, free carnitine and neurocognitive developmental assessments.


12. Prevention

For primary prevention, newborn tandem mass spectrometry (MS/MS)-based screening is the most effective. The key is to detect FAO disorders, including MCADD, before symptom onset through dried blood spot collection after 48 hours of life. Screen-positive newborns are immediately referred to a specialized metabolic disease center for confirmatory testing and treatment planning. When there is a family history, carrier status is determined through genetic counseling, and prenatal diagnostic options (CVS, amniocentesis, PGT) are offered. Secondary prevention is preventing metabolic crises in confirmed patients, and caregiver education (limiting fasting time, emergency protocol during infection, recognizing symptoms) is key. An emergency plan card is always carried, and a metabolic disease specialist is consulted before all surgery and anesthesia. In situations where long-distance travel or prolonged fasting is expected, snacks and an emergency plan are prepared in advance. For tertiary prevention, complications are detected early through regular metabolic monitoring (plasma acylcarnitine, free carnitine) and neurocognitive developmental assessment.


13. References

  1. Grosse SD, et al. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update. Genet Med. 2006;8(4):205-212. PMID: 16980815
  2. Spiekerkoetter U, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects. J Inherit Metab Dis. 2009;32(4):488-497. PMID: 19484594
  3. Arnold GL. Medium-chain acyl-CoA dehydrogenase deficiency. GeneReviews. NCBI Bookshelf. 2021. NBK1424.
  4. Lindner M, et al. Neonatal screening for MCAD deficiency: an evidence-based analysis. Eur J Pediatr. 2010;169(12):1309-1316. PMID: 20577773
  5. Andresen BS, et al. The molecular basis of MCAD deficiency in compound heterozygous patients. Hum Mol Genet. 1997;6(5):695-707. PMID: 9158143
  6. Derks TG, et al. The natural history of MCAD deficiency in the Netherlands. J Pediatr. 2006;148(5):665-670. PMID: 16737881
  7. Wilcken B, et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics. 2009;124(2):e241-248. PMID: 19581266
  8. Wanders RJ, et al. Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis. 1999;22(4):442-487. PMID: 10407780
  9. Impact of newborn screening for FAO disorders on neurological outcome: A Belgian retrospective multicentric study. Mol Genet Metab Rep. 2024. DOI: 10.1016/j.ymgmr.2024.100000
  10. MCADD Newborn Screening in Italy: Five Years Experience. Int J Neonatal Screen. 2025. PMC12550940.